Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Single Arm on the Tolerability of Weekly Nab-paclitaxel
LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer
Status: Enrolling
Updated:  12/31/1969
UNC Lineberger Comprehensive Cancer Center
344
mi
from 43215
Chapel Hill, NC
Single Arm on the Tolerability of Weekly Nab-paclitaxel
LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer
Status: Enrolling
Updated: 12/31/1969
UNC Lineberger Comprehensive Cancer Center
344
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
Single Arm on the Tolerability of Weekly Nab-paclitaxel
LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Rex Healthcare
370
mi
from 43215
Raleigh, NC
Single Arm on the Tolerability of Weekly Nab-paclitaxel
LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Rex Healthcare
370
mi
from 43215
Raleigh, NC
Click here to add this to my saved trials
Single Arm on the Tolerability of Weekly Nab-paclitaxel
LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
129
mi
from 43215
Cleveland, OH
Single Arm on the Tolerability of Weekly Nab-paclitaxel
LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
129
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Single Arm on the Tolerability of Weekly Nab-paclitaxel
LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center
420
mi
from 43215
Philadelphia, PA
Single Arm on the Tolerability of Weekly Nab-paclitaxel
LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
420
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Single Arm on the Tolerability of Weekly Nab-paclitaxel
LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
165
mi
from 43215
Pittsburgh, PA
Single Arm on the Tolerability of Weekly Nab-paclitaxel
LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
165
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Single Arm on the Tolerability of Weekly Nab-paclitaxel
LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Bon Secours Virginia Health System
335
mi
from 43215
Midlothian, VA
Single Arm on the Tolerability of Weekly Nab-paclitaxel
LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Bon Secours Virginia Health System
335
mi
from 43215
Midlothian, VA
Click here to add this to my saved trials
Single Arm on the Tolerability of Weekly Nab-paclitaxel
LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Swedish Cancer Institute
2006
mi
from 43215
Seattle, WA
Single Arm on the Tolerability of Weekly Nab-paclitaxel
LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Swedish Cancer Institute
2006
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer
Prevention of Death From Adenocarcinoma of the Lung by Low Dose Aspirin
Status: Enrolling
Updated:  12/31/1969
Vanderbilt-Ingram Cancer Center
334
mi
from 43215
Nashville, TN
Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer
Prevention of Death From Adenocarcinoma of the Lung by Low Dose Aspirin
Status: Enrolling
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
334
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Mechanisms of Immunosurveillance for Lung Cancer
Mechanisms of Immunosurveillance for Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
Mechanisms of Immunosurveillance for Lung Cancer
Mechanisms of Immunosurveillance for Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Grady Health System
436
mi
from 43215
Atlanta, GA
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Grady Health System
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Emory University Hospital Midtown
434
mi
from 43215
Atlanta, GA
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital Midtown
434
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Emory University/Winship Cancer Institute
432
mi
from 43215
Atlanta, GA
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Emory University/Winship Cancer Institute
432
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Siteman Cancer Center at Washington University
397
mi
from 43215
Saint Louis, MO
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Siteman Cancer Center at Washington University
397
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer
A Pilot Study of Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
559
mi
from 43215
Rochester, MN
Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer
A Pilot Study of Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
559
mi
from 43215
Rochester, MN
Click here to add this to my saved trials
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Highlands Oncology Group, P.A.
659
mi
from 43215
Fayetteville, AR
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Highlands Oncology Group, P.A.
659
mi
from 43215
Fayetteville, AR
Click here to add this to my saved trials
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Northeast Georgia Cancer Care
411
mi
from 43215
Athens, GA
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Northeast Georgia Cancer Care
411
mi
from 43215
Athens, GA
Click here to add this to my saved trials
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada
1767
mi
from 43215
Las Vegas, NV
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada
1767
mi
from 43215
Las Vegas, NV
Click here to add this to my saved trials
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematology Associate
514
mi
from 43215
Albany, NY
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematology Associate
514
mi
from 43215
Albany, NY
Click here to add this to my saved trials
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Hospital
480
mi
from 43215
New York, NY
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Hospital
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Unit (ITOR) Greenville Hospital System
360
mi
from 43215
Greenville, SC
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Unit (ITOR) Greenville Hospital System
360
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Accelerated Comm. Oncology Research Network (ACORN)
503
mi
from 43215
Memphis, TN
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Accelerated Comm. Oncology Research Network (ACORN)
503
mi
from 43215
Memphis, TN
Click here to add this to my saved trials
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
The West Clinic, PC
502
mi
from 43215
Memphis, TN
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
The West Clinic, PC
502
mi
from 43215
Memphis, TN
Click here to add this to my saved trials
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
US Oncology
975
mi
from 43215
The Woodlands, TX
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
US Oncology
975
mi
from 43215
The Woodlands, TX
Click here to add this to my saved trials
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Tyler Cancer Center
862
mi
from 43215
Tyler, TX
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Tyler Cancer Center
862
mi
from 43215
Tyler, TX
Click here to add this to my saved trials
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Northwest Cancer Specialists
2018
mi
from 43215
Vancouver, WA
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Northwest Cancer Specialists
2018
mi
from 43215
Vancouver, WA
Click here to add this to my saved trials
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Yakima Valley Memorial Hospital
1920
mi
from 43215
Yakima, WA
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Yakima Valley Memorial Hospital
1920
mi
from 43215
Yakima, WA
Click here to add this to my saved trials
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
mi
from 43215
London,
A Study of LY2940680 in Small Cell Lung Cancer
A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
mi
from 43215
London,
Click here to add this to my saved trials
Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Induced Oligometastatic Disease
A Randomized Phase II Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Induced Oligometastatic Disease
Status: Enrolling
Updated:  12/31/1969
University of Colorado
1161
mi
from 43215
Denver, CO
Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Induced Oligometastatic Disease
A Randomized Phase II Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Induced Oligometastatic Disease
Status: Enrolling
Updated: 12/31/1969
University of Colorado
1161
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Induced Oligometastatic Disease
A Randomized Phase II Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Induced Oligometastatic Disease
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Induced Oligometastatic Disease
A Randomized Phase II Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Induced Oligometastatic Disease
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Induced Oligometastatic Disease
A Randomized Phase II Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Induced Oligometastatic Disease
Status: Enrolling
Updated:  12/31/1969
London Health Sciences Centre
228
mi
from 43215
London,
Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Induced Oligometastatic Disease
A Randomized Phase II Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Induced Oligometastatic Disease
Status: Enrolling
Updated: 12/31/1969
London Health Sciences Centre
228
mi
from 43215
London,
Click here to add this to my saved trials
Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation
Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation
Status: Enrolling
Updated:  12/31/1969
Stanford University
2100
mi
from 43215
Palo Alto, CA
Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation
Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation
Status: Enrolling
Updated: 12/31/1969
Stanford University
2100
mi
from 43215
Palo Alto, CA
Click here to add this to my saved trials
Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation
Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
643
mi
from 43215
Boston, MA
Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation
Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation
Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation
Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation
Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering
477
mi
from 43215
New York, NY
Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation
Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering
477
mi
from 43215
New York, NY
Click here to add this to my saved trials
A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.
A Randomized Phase II Study of SUBATM-itraconazole With Cisplatin/Gemcitabine in Patients With Previously Untreated Metastatic Squamous Non-Small Cell Lung Cancer.
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University SKCCC
344
mi
from 43215
Baltimore, MD
A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.
A Randomized Phase II Study of SUBATM-itraconazole With Cisplatin/Gemcitabine in Patients With Previously Untreated Metastatic Squamous Non-Small Cell Lung Cancer.
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University SKCCC
344
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.
A Randomized Phase II Study of SUBATM-itraconazole With Cisplatin/Gemcitabine in Patients With Previously Untreated Metastatic Squamous Non-Small Cell Lung Cancer.
Status: Enrolling
Updated:  12/31/1969
Bayview Medical Center at Johns Hopkins
347
mi
from 43215
Baltimore, MD
A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.
A Randomized Phase II Study of SUBATM-itraconazole With Cisplatin/Gemcitabine in Patients With Previously Untreated Metastatic Squamous Non-Small Cell Lung Cancer.
Status: Enrolling
Updated: 12/31/1969
Bayview Medical Center at Johns Hopkins
347
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
INHERIT EGFR - Studying Germline EGFR Mutations
INHERIT EGFR - INvestigating HEreditary RIsk From T790M: A Multi-Centered Study to Identify and Characterize Individuals Carrying Germline EGFR Mutations
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
INHERIT EGFR - Studying Germline EGFR Mutations
INHERIT EGFR - INvestigating HEreditary RIsk From T790M: A Multi-Centered Study to Identify and Characterize Individuals Carrying Germline EGFR Mutations
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
INHERIT EGFR - Studying Germline EGFR Mutations
INHERIT EGFR - INvestigating HEreditary RIsk From T790M: A Multi-Centered Study to Identify and Characterize Individuals Carrying Germline EGFR Mutations
Status: Enrolling
Updated:  12/31/1969
The Ohio State University, Wexner Medical Center
1
mi
from 43215
Columbus, OH
INHERIT EGFR - Studying Germline EGFR Mutations
INHERIT EGFR - INvestigating HEreditary RIsk From T790M: A Multi-Centered Study to Identify and Characterize Individuals Carrying Germline EGFR Mutations
Status: Enrolling
Updated: 12/31/1969
The Ohio State University, Wexner Medical Center
1
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
INHERIT EGFR - Studying Germline EGFR Mutations
INHERIT EGFR - INvestigating HEreditary RIsk From T790M: A Multi-Centered Study to Identify and Characterize Individuals Carrying Germline EGFR Mutations
Status: Enrolling
Updated:  12/31/1969
Vanderbilt-Ingram Cancer Center
334
mi
from 43215
Nashville, TN
INHERIT EGFR - Studying Germline EGFR Mutations
INHERIT EGFR - INvestigating HEreditary RIsk From T790M: A Multi-Centered Study to Identify and Characterize Individuals Carrying Germline EGFR Mutations
Status: Enrolling
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
334
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Mitigation of Radiation Pneumonitis and Fibrosis
Mitigation of Radiation Pneumonitis and Fibrosis
Status: Enrolling
Updated:  12/31/1969
Clement J. Zablocki VA Medical Center, Milwaukee, WI
315
mi
from 43215
Milwaukee, WI
Mitigation of Radiation Pneumonitis and Fibrosis
Mitigation of Radiation Pneumonitis and Fibrosis
Status: Enrolling
Updated: 12/31/1969
Clement J. Zablocki VA Medical Center, Milwaukee, WI
315
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
Mitigation of Radiation Pneumonitis and Fibrosis
Mitigation of Radiation Pneumonitis and Fibrosis
Status: Enrolling
Updated:  12/31/1969
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
344
mi
from 43215
Baltimore, MD
Mitigation of Radiation Pneumonitis and Fibrosis
Mitigation of Radiation Pneumonitis and Fibrosis
Status: Enrolling
Updated: 12/31/1969
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
344
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Mitigation of Radiation Pneumonitis and Fibrosis
Mitigation of Radiation Pneumonitis and Fibrosis
Status: Enrolling
Updated:  12/31/1969
VA Ann Arbor Healthcare System, Ann Arbor, MI
163
mi
from 43215
Ann Arbor, MI
Mitigation of Radiation Pneumonitis and Fibrosis
Mitigation of Radiation Pneumonitis and Fibrosis
Status: Enrolling
Updated: 12/31/1969
VA Ann Arbor Healthcare System, Ann Arbor, MI
163
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
A RANDOMIZED PHASE I/II STUDY OF NAB-PACLITAXEL, OR PACLITAXEL, PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY FOLLoWED BY CONSOLIDATION IN PATIENTS WITH FAVORABLE PROGNOSIS INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC)
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center
910
mi
from 43215
Dallas, TX
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
A RANDOMIZED PHASE I/II STUDY OF NAB-PACLITAXEL, OR PACLITAXEL, PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY FOLLoWED BY CONSOLIDATION IN PATIENTS WITH FAVORABLE PROGNOSIS INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC)
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
A RANDOMIZED PHASE I/II STUDY OF NAB-PACLITAXEL, OR PACLITAXEL, PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY FOLLoWED BY CONSOLIDATION IN PATIENTS WITH FAVORABLE PROGNOSIS INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC)
Status: Enrolling
Updated:  12/31/1969
University of Rochester
354
mi
from 43215
Rochester, NY
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
A RANDOMIZED PHASE I/II STUDY OF NAB-PACLITAXEL, OR PACLITAXEL, PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY FOLLoWED BY CONSOLIDATION IN PATIENTS WITH FAVORABLE PROGNOSIS INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC)
Status: Enrolling
Updated: 12/31/1969
University of Rochester
354
mi
from 43215
Rochester, NY
Click here to add this to my saved trials
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
A RANDOMIZED PHASE I/II STUDY OF NAB-PACLITAXEL, OR PACLITAXEL, PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY FOLLoWED BY CONSOLIDATION IN PATIENTS WITH FAVORABLE PROGNOSIS INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC)
Status: Enrolling
Updated:  12/31/1969
UPMC Cancer Center
166
mi
from 43215
Pittsburgh, PA
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
A RANDOMIZED PHASE I/II STUDY OF NAB-PACLITAXEL, OR PACLITAXEL, PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY FOLLoWED BY CONSOLIDATION IN PATIENTS WITH FAVORABLE PROGNOSIS INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC)
Status: Enrolling
Updated: 12/31/1969
UPMC Cancer Center
166
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
A RANDOMIZED PHASE I/II STUDY OF NAB-PACLITAXEL, OR PACLITAXEL, PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY FOLLoWED BY CONSOLIDATION IN PATIENTS WITH FAVORABLE PROGNOSIS INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute
333
mi
from 43215
Nashville, TN
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
A RANDOMIZED PHASE I/II STUDY OF NAB-PACLITAXEL, OR PACLITAXEL, PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY FOLLoWED BY CONSOLIDATION IN PATIENTS WITH FAVORABLE PROGNOSIS INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
A RANDOMIZED PHASE I/II STUDY OF NAB-PACLITAXEL, OR PACLITAXEL, PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY FOLLoWED BY CONSOLIDATION IN PATIENTS WITH FAVORABLE PROGNOSIS INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Vanderbilt-Ingram Cancer Center
334
mi
from 43215
Nashville, TN
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
A RANDOMIZED PHASE I/II STUDY OF NAB-PACLITAXEL, OR PACLITAXEL, PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY FOLLoWED BY CONSOLIDATION IN PATIENTS WITH FAVORABLE PROGNOSIS INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
334
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
Phase I Study of Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
Phase I Study of Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer
A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
506
mi
from 43215
Jonesboro, AR
A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer
A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
506
mi
from 43215
Jonesboro, AR
Click here to add this to my saved trials
A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer
A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer
A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials